Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Achaogen

Evaluate

Thumbnail
November 20, 2018

Patience is a virtue for big pharma buyers

For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.

Thumbnail
August 13, 2018

After Alnylam’s solo maiden launch, here comes the tricky bit

Alnylam has secured its first approval, but history suggests that launch will be far from easy.

Vantage logo
June 29, 2018

Snippet roundup: Approvals for Array and Dermira, but Achaogen falls short

Article image
Vantage logo
June 08, 2018

Upcoming events – Array and Achaogen head to US regulators

It's all about the label for plazomicin, and Array’s Braf-Mek project stacks up well against the competition.

Vantage logo
May 04, 2018

Snippet roundup: The good times roll for Moderna, but Mallinckrodt and Smith & Nephew flag

Vantage logo
April 20, 2018

Upcoming events – Panel decisions due for Achaogen and Akcea

Vantage logo
February 14, 2018

Intravenous inferiority makes it two failures for Tetraphase

Vantage logo
November 30, 2017

Medicines Company shows that there’s money in antibiotics after all

Vantage logo
April 06, 2017

Mid-cap biopharma stocks pick up in the first quarter

Vantage logo
December 13, 2016

Epic antibiotic data could spur interest in Achaogen

Vantage logo
December 02, 2016

Upcoming events – Achaogen’s antibiotic and Nektar tries out its opioid again

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up